Please login to the form below

morphosys

This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.

MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss

Therapy candidate was licensed in a $1bn-plus deal last year. Germany’s MorphoSys has abandoned an atopic dermatitis drug licensed by Novartis in a $1bn-plus deal last year after ... The decision to drop MOR106, a selective IL-17c inhibitor

Latest news

FDA verdict on Sanofi’s Darzalex rival is due in April 2020

Additional competition is however looming from MorphoSys and Takeda, which each have anti-CD38 drugs in pivotal-stage testing for myeloma, while another rival is Bristol-Myers Squibb and AbbVie’s
GSK pushes rheumatoid arthritis antibody into phase 3

GSK acquired the rights to otilimab from MorphoSys in a 445m deal agreed in 2013, and the German biotech stands to a receive a 22m milestone payment with the start of
MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

New trial data has set up a US filing later this year for MorphoSys’ anti-CD19 antibody tafasitamab (MOR208) – and a possible challenge to Novartis and Gilead’s CAR-T therapies. ... The L-MIND data raise the likelihood of MorphoSys attracting a
Janssen looks to expand Darzalex in Europe

Additionally, both MorphoSys and Takeda each have their own myeloma drugs in mid-stage testing and Bristol-Myers Squibb and AbbVie are hoping that SLAMF7 targeting Empliciti, in combination with Revlimid,
Sanofi's Darzalex rival scores in myeloma trial

In the meantime, additional anti-CD38 competition is looming from the likes of MorphoSys with MOR202 and Takeda with TAK-079, both in mid-stage testing, while J&J and Genmab

More from news
Approximately 4 fully matching, plus 16 partially matching documents found.

Latest Intelligence

European biotech: a new generation of leaders emerges

Morphosys. One of Europe’s star performers over the last two to three years has been Germany’s Morphosys. ... Unlike many other European biotechs, Morphosys isn’t seeking a marketing partner for the launch of its lead product, and aims to go it
Deal Watch November 2016

acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.
Pharma deals in March 2015

In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an
Deal Watch table for August 2014

187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
Pharma deals during August 2014

These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.

More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.

Latest appointments

Pharma industry appointments

Lemus was also chief executive officer of Sigma Tau Pharmaceuticals and chief financial officer and executive vice president of MorphoSys, where he took the company public in 1999.
Robert Freisen joins Ablynx

He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
Dave Lemus joins Proteros as an executive board member

He has also held roles with MorphoSys and Hoffman La Roche.
MorphoSys appoints Dr Markus Enzelberger as CSO

He succeeds Dr Marlies Sproll who resigns. German biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation. ... Dr Gerald Moller, supervisory board chairman,
MC Services welcomes Dr Claudia Gutjahr-Loeser to its management team

She joins the PR firm from MorphoSys, where she was senior VP. ... She joins the Duesseldorf, Germany-based firm from MorphoSys, where she headed the corporate communications and investor relations department as senior vice president; a role that saw her

More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.

Featured jobs

Scientific Director - Medical Communications - Berkshire: Excellent package on offer

Graduate Scientific Editor: DOE

Editorial Team Leader – Medical Communications – Buckinghamshire...: Salary TBC

Medical Writer – Very Flexible Working – Surrey: Negotiable

Account Director: Salary TBC

Senior Editor - Medical Communications - South East - Buckingham...: Highly competitive salary &package

Account Director, Healthcare Communications Agency: £54, 000- £60, 000

Account Director, Medical Education: Salary TBC

Account Executive: Salary TBC

Account Manager, Healthcare Communications: £32, 000 - £40, 000 bonus benefits

Senior Medical Writer: Salary TBC

Account Supervisor: Salary TBC

Entry Level Editorial Assistant – Medical Education –Buckinghams...: Highly Competitive

Subscribe to our email news alerts

PMHub

Add my company

Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

RWE Blog 3: Is real-world evidence the holy grail: We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...
What do Healthcare Professionals think about the inclusion of remote selling techniques?: Evolving to a digitally focused pharma / healthcare company - an organisational roadmap...
Strengthening business competition and reducing anti-competitive practices: How the CMA is tackling high prices for essential drugs...